WO2004089942A3 - Derives de benzimidazolidinone utilises en tant qu'agents muscariniques - Google Patents

Derives de benzimidazolidinone utilises en tant qu'agents muscariniques Download PDF

Info

Publication number
WO2004089942A3
WO2004089942A3 PCT/US2004/009859 US2004009859W WO2004089942A3 WO 2004089942 A3 WO2004089942 A3 WO 2004089942A3 US 2004009859 W US2004009859 W US 2004009859W WO 2004089942 A3 WO2004089942 A3 WO 2004089942A3
Authority
WO
WIPO (PCT)
Prior art keywords
muscarinic agents
benzimidazolidinone
benzimidazolidinone derivatives
derivatives
compounds
Prior art date
Application number
PCT/US2004/009859
Other languages
English (en)
Other versions
WO2004089942A2 (fr
Inventor
Nicholas Michael Kelly
Kristian Norup Koch
Bo-Ragnar Tolf
Original Assignee
Acadia Pharm Inc
Nicholas Michael Kelly
Kristian Norup Koch
Bo-Ragnar Tolf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/262,517 external-priority patent/US7087593B2/en
Priority claimed from US10/408,192 external-priority patent/US6951849B2/en
Application filed by Acadia Pharm Inc, Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf filed Critical Acadia Pharm Inc
Publication of WO2004089942A2 publication Critical patent/WO2004089942A2/fr
Publication of WO2004089942A3 publication Critical patent/WO2004089942A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés dérivés de benzimidazolidinone qui augmentent la signalisation ou l'effet de l'acétylcholine dans le cerveau, ainsi que des agonistes muscariniques hautement sélectifs, notamment les sous-types des récepteurs M1 et/ou M4. L'invention concerne également des compositions pharmaceutiques contenant lesdits composés, ainsi que des méthodes de traitement de la psychose utilisant ces composés.
PCT/US2004/009859 2001-10-02 2004-03-30 Derives de benzimidazolidinone utilises en tant qu'agents muscariniques WO2004089942A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US32675401P 2001-10-02 2001-10-02
US10/262,517 US7087593B2 (en) 2001-10-02 2002-09-30 Benzimidazolidinone derivatives as muscarinic agents
US40675003A 2003-04-02 2003-04-02
US10/406,750 2003-04-02
US10/408,192 2003-04-03
US10/408,192 US6951849B2 (en) 2001-10-02 2003-04-03 Benzimidazolidinone derivatives as muscarinic agents

Publications (2)

Publication Number Publication Date
WO2004089942A2 WO2004089942A2 (fr) 2004-10-21
WO2004089942A3 true WO2004089942A3 (fr) 2004-11-25

Family

ID=46150402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009859 WO2004089942A2 (fr) 2001-10-02 2004-03-30 Derives de benzimidazolidinone utilises en tant qu'agents muscariniques

Country Status (1)

Country Link
WO (1) WO2004089942A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550459B2 (en) * 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
CA2580621A1 (fr) * 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd Nouveaux antibiotiques bicycliques
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
DE602006019119D1 (de) 2005-09-30 2011-02-03 Glaxo Group Ltd Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin
US8288412B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
JP5209479B2 (ja) 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有するベンゾイミダゾロン類
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
GB0605784D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0605786D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
TW200815405A (en) * 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
TW200813018A (en) * 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
AR068480A1 (es) 2007-09-20 2009-11-18 Glaxo Group Ltd Compuesto de 4-heteroaril-piperidinil-n-substituido su uso para la preparacion de un medicamento util para el tratamiento de una afeccion en el que seria beneficioso el agonismo de un receptor muscarinico m1 y composicion farmaceutica que lo comprende
WO2009037294A1 (fr) * 2007-09-20 2009-03-26 Glaxo Group Limited Composés présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine
GB0718415D0 (en) 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
ME02663B (fr) 2010-10-06 2017-06-20 Glaxosmithkline Llc Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase
US9187451B2 (en) 2011-11-18 2015-11-17 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
IL272284B2 (en) 2017-08-01 2024-01-01 Merck Patent Gmbh History of thiazolopyridines, their preparation and pharmaceutical preparations containing them
AU2018320672B2 (en) 2017-08-21 2023-09-07 Merck Patent Gmbh Quinoxaline derivatives as adenosine receptor antagonists
TWI791593B (zh) 2017-08-21 2023-02-11 德商馬克專利公司 做為腺苷受體拮抗劑之苯并咪唑衍生物
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
ES2960883T3 (es) 2018-10-25 2024-03-07 Merck Patent Gmbh Derivados de 5-azaindazol como antagonistas de los receptores de adenosina
BR112021007727A2 (pt) 2018-10-25 2021-07-27 Merck Patent Gmbh derivados de 5-azaindazol como antagonistas receptores de adenosina
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
AR117844A1 (es) 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254127A (en) * 1980-04-03 1981-03-03 Janssen Pharmaceutica, N.V. 1,3-Dihydro-1-[(1-piperidinyl)alkyl]-2H-benzimidazol-2-one derivatives
WO1996013262A1 (fr) * 1994-10-27 1996-05-09 Merck & Co., Inc. Antagonistes de muscarine
WO1999032481A1 (fr) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements
WO2001083472A1 (fr) * 2000-04-28 2001-11-08 Acadia Pharmaceuticals, Inc. Agonistes muscariniques
WO2003028650A2 (fr) * 2001-10-02 2003-04-10 Acadia Pharmaceuticals, Inc. Derives de benzimidazolidinone utilises comme agents muscariniques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254127A (en) * 1980-04-03 1981-03-03 Janssen Pharmaceutica, N.V. 1,3-Dihydro-1-[(1-piperidinyl)alkyl]-2H-benzimidazol-2-one derivatives
WO1996013262A1 (fr) * 1994-10-27 1996-05-09 Merck & Co., Inc. Antagonistes de muscarine
WO1999032481A1 (fr) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements
WO2001083472A1 (fr) * 2000-04-28 2001-11-08 Acadia Pharmaceuticals, Inc. Agonistes muscariniques
WO2003028650A2 (fr) * 2001-10-02 2003-04-10 Acadia Pharmaceuticals, Inc. Derives de benzimidazolidinone utilises comme agents muscariniques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAKIR B ET AL: "SYNTHESIS AND ANTINOCICEPTIVE ACTIVITY OF SOME 3-SUBSTITUTED BENZOTHIAZOLONE DERIVATIVES", FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 54, 1999, pages 846 - 851, XP001022237, ISSN: 0014-827X *

Also Published As

Publication number Publication date
WO2004089942A2 (fr) 2004-10-21

Similar Documents

Publication Publication Date Title
WO2003028650A3 (fr) Derives de benzimidazolidinone utilises comme agents muscariniques
WO2004089942A3 (fr) Derives de benzimidazolidinone utilises en tant qu&#39;agents muscariniques
HUP0401777A3 (en) 3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds
WO2000066590A3 (fr) Composes modulateurs de recepteur de progesterone tetracycliques et procedes
WO2008064351A3 (fr) (r)-n-stéréoisomères d&#39;analogues 4,5-époxy-morphinanium saturé en position 7 et 8
WO2000006085A3 (fr) Composes et procedes
ZA200501082B (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
AP1869A (en) b2- Adrenergic receptor agonists.
MY145074A (en) Thiazolidin-4-one derivatives
HUP0401849A3 (en) Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
BRPI0413234A (pt) derivados de imidazola bicìclica contra flaviviridae
WO2006047516A3 (fr) Composes et compositions servant d&#39;inhibiteurs d&#39;activite de recepteur cannabinoide de type 1
IL216579A0 (en) Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same
WO2006044362A3 (fr) Antagonistes du recepteur 1 de n-sulfonylpiperidine cannabinoide
HK1077193A1 (en) Alpha-7 nicotinic receptor agonists and statins incombination
WO2005030188A3 (fr) Derives de phenyl-piperazine en tant que modulateurs des recepteurs muscariniques
WO2003057145A3 (fr) 4,9-dihydrocyclopenta[imn]phenanthridine-5-ones substitues, leurs derives et leurs utilisations
WO2004009091A8 (fr) Agonistes des recepteurs x du foie
WO2005089294A3 (fr) Synthese d&#39;indenoisoquinoliniums et techniques d&#39;utilisation
WO2007034278A3 (fr) Antagonistes du recepteur du c3a
WO2005033112A3 (fr) Derives d&#39;indole substitues
WO2005019200A3 (fr) Derives d&#39;arylpiperidine utilises en tant qu&#39;antagonistes d&#39;integrine vla-1 et utilisations de ceux-ci
WO2001087287A3 (fr) Composes actifs sur le plan pharmaceutiques et procedes d&#39;utilisation
HUP0201710A2 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor, process for producing them and pharmaceutical compositions containing them
WO2007007282A3 (fr) Antagonistes des recepteurs muscariniques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase